{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:10:12Z","timestamp":1785161412992,"version":"3.55.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections are among the most important global health issues. Virus-directed CAR-T and CAR-NK are promising strategies capable of targeting virally infected cells. The therapeutic potential, safety, and translational readiness of these platforms have not been fully synthesised.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study assessed preclinical and early clinical evidence of CAR-T and CAR-NK immunotherapies against HBV and HIV, including efficacy, safety and translational feasibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Databases were searched according to PRISMA 2020 guidelines. For this review, eligible studies included\n                      <jats:italic>in vitro<\/jats:italic>\n                      ,\n                      <jats:italic>in vivo<\/jats:italic>\n                      , and clinical studies examining virus-directed CAR lymphocytes. Random-effects models generated pooled standardised mean differences (SMD) and risk ratios (RR). The level of specific evidence was considered by GRADE.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty-three studies met the inclusion criteria (21\n                      <jats:italic>in vitro<\/jats:italic>\n                      , 14\n                      <jats:italic>in vivo<\/jats:italic>\n                      , and 8 clinical). Preclinical HIV CAR-T models demonstrated significant reductions in HIV p24 antigen levels (pooled SMD = \u22121.15, 95% CI \u22121.50 to \u22120.80). Similarly, HBV-directed engineered T-cell studies showed a marked decrease in HBsAg and HBV DNA (SMD = \u22121.30, 95% CI \u22121.70 to \u22120.90). CAR-NK platforms displayed comparable antiviral activity with potentially improved safety profiles. In vivo analyses also indicated consistent suppression of HIV RNA (SMD = \u22120.92, 95% CI \u22121.26 to \u22120.58) and moderate reductions in HBV DNA levels (SMD = \u22121.05, 95% CI \u22121.52 to \u22120.63). In early-phase clinical studies (phase I\/II), HIV-directed CAR-T therapies produced modest decreases in circulating HIV RNA (SMD = \u22120.35, 95% CI \u22120.60 to \u22120.12), while HBV-targeted therapies demonstrated small but detectable antiviral responses (SMD = \u22120.42, 95% CI \u22120.78 to \u22120.11). Across clinical cohorts, the incidence of cytokine release syndrome (CRS) remained low, occurring in fewer than 10% of treated patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Virus-directed CAR-T and CAR-NK therapies show strong preclinical antiviral activity and early clinical signs of activity, showing acceptable safety. Because of heterogeneity, small sample size and limited clinical data, the quality of evidence from this population remains low to moderate. Large and well-controlled trials are necessary to optimise CAR designs, improve persistence, and investigate combinations with latency-reversing or immune-modulating drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1768365","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:59:16Z","timestamp":1774533556000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Virus-directed CAR immunotherapies for chronic HBV and HIV: a systematic synthesis of preclinical and early clinical evidences"],"prefix":"10.3389","volume":"13","author":[{"given":"Sirwan","family":"Sleman","sequence":"first","affiliation":[{"name":"College of Veterinary Medicine, University of Sulaimani","place":["Sulaymaniyah, Iraq"]},{"name":"Nursing Department, National Institute of Technology","place":["Sulaymaniyah, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masood B.","family":"Ameen","sequence":"additional","affiliation":[{"name":"Sulaimani Private Veterinary Hospital","place":["Sulaymaniyah, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omed I.","family":"Abid","sequence":"additional","affiliation":[{"name":"Masi Altuni Company","place":["Sulaymaniyah, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barham J.","family":"Abdullah","sequence":"additional","affiliation":[{"name":"Sulaimani Private Veterinary Hospital","place":["Sulaymaniyah, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaniar A.","family":"Abass","sequence":"additional","affiliation":[{"name":"Masi Altuni Company","place":["Sulaymaniyah, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1565621","DOI":"10.3389\/fpubh.2025.1565621","article-title":"Prevalence and burden of HBV\u2013HIV co-morbidity: a global systematic review and meta-analysis","volume":"13","author":"Dagnaw","year":"2025","journal-title":"Front Public Health"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.3390\/v17121615","article-title":"CAR-T cell therapy for HIV cure: current challenges","volume":"17","author":"Padurariu-Covit","year":"2025","journal-title":"Advances and future directions."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"636775","DOI":"10.3389\/fimmu.2021.636775","article-title":"Humanized mice for the evaluation of novel HIV-1 therapies","volume":"12","author":"Abeynaike","year":"2021","journal-title":"Front Immunol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Molecular Ther Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1097\/CM9.0000000000002904","article-title":"Targeting the HIV reservoir: chimeric antigen receptor therapy for HIV cure","volume":"136","author":"Li","year":"2023","journal-title":"Chin Med J"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2546404","DOI":"10.1080\/2162402X.2025.2546404","article-title":"CAR-T cell engineered with TCR-like antibody specific for HBV surface antigen epitope E183-91\/HLA-A *0201 exhibit potent activity against HBV-HCC","volume":"14","author":"Wang","year":"2025","journal-title":"Oncoimmunol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in vivo","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat Biotechnol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.3389\/fimmu.2019.01234","article-title":"CAR-NK cells targeting HIV-infected cells","volume":"10","author":"Guo","year":"2019","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"626431","DOI":"10.3389\/fimmu.2020.626431","article-title":"A matter of life or death: productively infected and bystander CD4 T cells in early HIV infection","volume":"11","author":"Cao","year":"2021","journal-title":"Front Immunol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/hepr.13334","article-title":"HBV CAR-T cells demonstrate antiviral efficacy in humanized mouse models","volume":"49","author":"Yu","year":"2019","journal-title":"Hepatol Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008827","article-title":"First-in-human HIV CAR-T cell therapy","volume":"6","author":"Scholler","year":"2014","journal-title":"Sci Transl Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.jhep.2021.11.029","article-title":"Early-phase clinical trial of HBV CAR-T cells in chronic hepatitis B","volume":"76","author":"Huang","year":"2022","journal-title":"J Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/infdis\/jiy049","article-title":"HIV-specific CAR-T cell therapy in patients on ART","volume":"217","author":"Deeks","year":"2018","journal-title":"J Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.coviro.2019.04.004","article-title":"Development of CAR-T cells for long-term eradication and surveillance of HIV-1 reservoir","volume":"38","author":"Liu","year":"2019","journal-title":"Curr Opin Virol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1200\/JCO-24-02424","article-title":"Results from first-in-human phase I study of a novel CD19-1XX chimeric antigen receptor with calibrated Signaling in large B-cell lymphoma","volume":"43","author":"Park","year":"2025","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"110775","DOI":"10.1016\/j.humimm.2024.110775","article-title":"Lower NKG2D expression in hepatic natural killer cells predicts poorer prognosis for chronic hepatitis B patients with cirrhosis","volume":"85","author":"Ma","year":"2024","journal-title":"Hum Immunol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"724211","DOI":"10.3389\/fimmu.2021.724211","article-title":"Reducing hinge flexibility of CAR-T cells prolongs survival in vivo with low cytokines release","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1038\/s41375-020-0936-4","article-title":"Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection","volume":"34","author":"Wang","year":"2020","journal-title":"Leukemia"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"103066","DOI":"10.1016\/j.transci.2021.103066","article-title":"Establishment of a cell processing laboratory to support hematopoietic stem cell transplantation and chimeric antigen receptor (CAR)-T cell therapy","volume":"60","author":"Mukherjee","year":"2021","journal-title":"Transfus Apher Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.cell.2020.03.039","article-title":"Pooled Knockin targeting for genome engineering of cellular immunotherapies","volume":"181","author":"Roth","year":"2020","journal-title":"Cell"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1106700","DOI":"10.3389\/fimmu.2023.1106700","article-title":"Abnormally primed CD8 T cells: the Achilles\u2019 heel of CHB","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"664920","DOI":"10.3389\/fimmu.2021.664920","article-title":"HBV-targeted CAR-T cells in animal models: efficacy and safety","volume":"12","author":"Tang","year":"2021","journal-title":"Front Immunol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/bjh.16951","article-title":"Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy","volume":"191","author":"Liu","year":"2020","journal-title":"British J Haematol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s10238-025-01851-4","article-title":"HBV reprograms the tumor microenvironment in hepatocellular carcinoma: mechanisms and therapeutic implications","volume":"26","author":"Shen","year":"2026","journal-title":"Clin Exper Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1154321","DOI":"10.3389\/fimmu.2023.1154321","article-title":"Next-generation HBV CAR-T cells with enhanced persistence","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Immunol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1604490","DOI":"10.3389\/fimmu.2025.1604490","article-title":"Case report of non-gene editing CD7 CAR T cell therapy in CD7+ S\u00e9zary syndrome: preclinical validation and first-in-human use","volume":"16","author":"Xu","year":"2025","journal-title":"Front Immunol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e70303","DOI":"10.1002\/jmv.70303","article-title":"Extrathymic CD8 and CD4 double positive T cells presenting vigorous HBV-specific responses accelerate HBV clearance","volume":"97","author":"Fang","year":"2025","journal-title":"J Med Virol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1768365\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:59:18Z","timestamp":1774533558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1768365\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":29,"alternative-id":["10.3389\/fmed.2026.1768365"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1768365","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"article-number":"1768365"}}